The introduction of nicotinamide as being a nicotine substitute in e-cigarette and smokeless goods represents a major regulatory obstacle for your FDA. Nicotinamide doesn't have nicotinic receptor agonist activity and is known to act as a sedative at substantial dosages6. The statements created